News Tag: Other Corporate Information - Page 2

XVIVO granted Breakthrough Device Designation from the FDA for the Liver Assist device

  • 05:30

XVIVO has been granted Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for their Liver Assist device, indicated for ex-vivo oxygenated machine perfusion for preservation of donor livers prior to transplantation. The FDA’s Breakthrough Device Program is intended to expedite the development and prioritize the regulatory review of certain medical devices that provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions than previous therapies.

Read more

Conference call on Interim Report

  • 06:30

Invitation to attend XVIVO’s conference call regarding the presentation of the interim report January-June 2022. The presentation will be held in English.

Read more

CHU Toulouse i Frankrike introducerar program för maskinperfusion för lever och lunga med hjälp av XVIVOs teknologier

  • 13:00

Sjukhuset CHU Toulouse i Frankrike har nu introducerat program för maskinperfusion för både lever och lunga. I och med det är det möjligt för dem att signifikant öka antalet transplantationer. Under ett normalt år utför sjukhuset cirka 45 levertransplantationer och cirka 20 lungtransplantationer och därmed uppfyller de redan den lokala kravpolicyn för organtransplantation. De nya programmen för maskinperfusion öppnar också upp för användning av organ som donerats efter cirkulationsstillestånd (DCD).

Read more

CHU Toulouse in France starts liver and lung perfusion programs using XVIVO technologies

  • 13:00

The CHU Toulouse hospital in France has introduced both a liver and a lung machine perfusion program, now having the ability to significantly increase their transplant numbers. In a normal year they perform about 45 liver transplants and about 20 lung transplants and by that already fulfill the local requirement policy for organ transplantation. The machine perfusion programs also allow for utilization of organs donated after circulatory death (DCD).

Read more